JPWO2012101846A1 - Influenza treatment or prevention - Google Patents

Abstract

A therapeutic or prophylactic agent for influenza infections whose action mechanism is to effectively improve ATP depletion, and is diisopropylamine dichloroacetate (DADA), DADA and gluconic acid or salts thereof, or DADA and gluconic acid Or a drug containing the salt and vitamin B1.

Description

  The present invention relates to a therapeutic or prophylactic agent for influenza containing diisopropylamine dichloroacetate (hereinafter sometimes simply referred to as DADA).

  Influenza is an acute respiratory infection, especially in children and the elderly, with a strong tendency to become severe, especially in children where influenza encephalopathy and multiple organ failure occur frequently. Thus, it is considered that the mechanism by which flu-affected persons become severe is mainly caused by inflammatory cytokines / reactive oxygens overproduced by viral infection, which damage the vascular endothelium (cytokine storm). In other words, influenza encephalopathy is rapid cerebral edema due to increased permeability of the vascular endothelium of the brain, and multi-organ failure is considered to be peripheral circulatory failure due to increased permeability of vascular endothelial cells throughout the body (Non-patent Document 1). However, vascular endothelium damage is more or less common to those affected by the virus, and it does not explain the severity of the disease, especially in children.

  On the other hand, carnitine palmitoyl transferase (Carnitine palmitoyltrasferase 2: CPT2), a fatty acid metabolizing enzyme, has a polymorphism peculiar to Japanese people. The present inventors have found for the first time and have actually proved that the fatty acid metabolism disorder of this cause has occurred, resulting in the depletion of systemic ATP (Non-patent Document 2).

Wang S. et al. J. Infect. Dis. 202 (7): 991-1001, 2010 Yao D. et al. Hum. Mutat. 29 (5): 718-727, 2008

  In general, children are known to have a high fat energy ratio (the ratio of fat energy to the total energy). The present inventors have presumed that this is due to systemic ATP depletion due to heat inactivation. In particular, tissues that are susceptible to symptoms due to fatty acid metabolism disorders are vascular endothelial cells that depend on fatty acid metabolism for about 70% of the energy source (Zeina Dagher et al. Circ. Res. 88: 1276-1282, 2001). Therefore, the present inventors conclude for the first time by induction that peripheral circulatory insufficiency is likely to occur in patients (children) with congenital or acquired fatty acid metabolism disorders at the time of influenza. It came.

  Based on this reasoning, the present inventors have found that a fatty acid metabolism-improving drug or a glucose metabolism-improving drug, which is an alternative energy production system for fatty acid metabolism, becomes an active ingredient of a therapeutic or preventive drug for influenza virus infection. I came up with the idea that I might get it. Therefore, in the body metabolism, fatty acid metabolism and sugar metabolism are closely related to each other, so if one of them decreases, the other is activated and maintained in the direction of maintaining the ATP level in the body. Therefore, the inventors have come up with the idea that a drug that improves sugar metabolism is useful for this purpose.

  As sugar metabolism improving drugs, for example, dichloroacetic acid diisopropylamine (DADA), octothiamine, benfothiamine, and the like are known. In particular, DADA is known to have an anti-fatigue effect in combination with vitamin B1 (especially benfotiamine) and gluconic acid in addition to the glucose metabolism improving effect (Japanese Patent Laid-Open No. 2010-138170). However, it has not been known at all that DADA is effective in treating or preventing influenza virus infection.

  That is, the present invention shows that the seriousness of influenza virus infection and the resulting death are manifestations of systemic ATP depletion caused by virus infection, and become severe by improving the depletion of ATP. The goal is to provide a means of treating or preventing influenza based on a new mechanism of action that can prevent death.

The present invention provides the following to solve the above-described problems.
(1) A therapeutic or prophylactic agent for influenza virus infection containing diisopropylamine dichloroacetate (DADA).
(2) The therapeutic or prophylactic agent according to (1), further containing gluconic acid or a salt thereof.
(3) The therapeutic or prophylactic agent according to (2), further comprising vitamin B1.
(4) The treatment according to any one of (1) to (3) above, wherein the influenza virus is a seasonal influenza virus type A or B, a new influenza virus (influenza virus H1N1 2009), or a highly pathogenic influenza virus Agent or prophylactic agent.
(5) A method for treating or preventing influenza virus infection, comprising administering an effective amount of the agent described in any of (1) to (4) above to a mammal.

  According to the present invention, it becomes possible to effectively prevent or treat the severity of symptoms caused by systemic ATP depletion due to influenza virus infection. The drug of the present invention is also effective in suppressing weight loss associated with influenza infection, suppressing appetite loss, and suppressing ATP depletion.

It is a result of test example 1, A shows a change of survival rate of a mouse, and B shows a change of body weight. It is a result of Experiment 2, A shows the change of the survival rate of a mouse | mouth, B shows the change of a body weight. It is a result of Experiment 3, A shows the change of the survival rate of a mouse | mouth, B shows the change of a body weight. It is a result of test example 3, A shows change of the amount of food intake of a mouse, and B shows change of the amount of water intake. It is a result of test example 4, A shows a change of survival rate of a mouse, and B shows a change of body weight. It is a result of test example 4, A shows change of the amount of food intake of a mouse, and B shows change of the amount of water intake. It is a result of test example 5, A shows the change of the survival rate of a mouse | mouth, B shows the change of a body weight. It is a result of Experiment 5, A shows the change of the amount of water intake of a mouse | mouth, B shows the change of the amount of food intake. It is a result of Experiment 6, and is a measured value of each of a blood glucose level, a blood lactic acid level, a blood β-hydroxybutyric acid value, and a blood ATP value. It is a result of Test Example 7 and is a measurement value of ATP amount in each of brain, heart, liver, and muscle. It is a result of Test Example 8, and is a measured value of PDH (Pyruvate dehydrogenase) activity in each of brain, heart, liver, and muscle.

  A commercially available product (for example, Lot. XVA8056 manufactured by Daiichi Sankyo Co., Ltd.) can be used as the DADA used for the drug of the present invention.

  The content of DADA is preferably designed so that it can be taken 1 to 20000 mg, more preferably 3 to 3000 mg divided into 1 to 3 times a day. For example, if the drug of the present invention is a liquid that is taken 100 mL once a day, the DADA content in the liquid is preferably 1 to 20000 mg / 100 mL, more preferably 3 to 3000 mg / 100 mL.

  One of the preferable embodiments of the drug of the present invention is to contain gluconic acid or a salt thereof together with DADA. Gluconic acid is known as one of the active ingredients of the composition for colds or influenza (Japanese Patent Laid-Open No. 2001-172184), and one component of a drug for inactivating avian influenza virus (Japanese Patent Laid-Open No. 2010-2010). -143875)), however, the effect of combined use with DADA in the treatment or prevention of influenza virus infection has not been known at all.

  Examples of the salt of gluconic acid include sodium gluconate, calcium gluconate, magnesium gluconate and the like, and sodium gluconate or calcium gluconate is preferable. These compounds are listed in the Pharmaceutical Additive Dictionary 2000 and the like.

  The content of gluconic acid or a salt thereof in the medicament of the present invention is preferably designed so that it can be taken in an amount of 1 to 20000 mg, more preferably 3 to 3000 mg divided into 1 to 3 times a day. For example, if the drug of the present invention is a liquid that is taken 100 mL once a day, the content of gluconic acid or a salt thereof in the liquid is preferably 1 to 20000 mg / 100 mL, more preferably 3 to 3000 mg / 100 mL . In the drug of the present invention, gluconic acid and gluconate may be used in combination. In that case, the total content of gluconic acid and gluconate may be in the above range.

  Further, the blending ratio (weight ratio) of DADA and gluconic acid or a salt thereof is not particularly limited as long as the effect of the present invention is exhibited.

  Another preferred embodiment of the medicament of the present invention is to contain gluconic acid or a salt thereof and vitamin B1 together with DADA.

  Examples of vitamin B1 include thiamine hydrochloride, thiamine nitrate, benfotiamine, fursultiamine, octothiamine and the like, and thiamine hydrochloride or benfotiamine is preferable. These compounds are listed in the 15th revision Japanese Pharmacopoeia, Pharmaceutical Additives Standard 2003, and the like.

  The content of vitamin B1 in the drug of the present invention is preferably set to be 0.1 to 300 mg, more preferably 1 to 200 mg, which can be taken 1 to 3 times a day. For example, if the drug of the present invention is a liquid that is taken 100 mL once a day, the content of vitamin B1 in the liquid is preferably 0.1 to 300 mg / 100 mL, more preferably 1 to 200 mg / 100 mL.

  Further, the blending ratio (weight ratio) of DADA and the sum of gluconic acid or a salt thereof and vitamin B1 is not particularly limited as long as the effect of the present invention is exhibited.

  As long as the effect of the present invention is not inhibited, the drug of the present invention can be further supplemented with vitamins other than vitamin B1, pyruvic acid or salts thereof, caffeine, minerals, amino acids, herbal medicines, other organic acids, Excipients, binders, lubricants, coating agents, preservatives, colorants, stabilizers, pH adjusters, solubilizers, cooling agents, fragrances, pigments / colorants, and the like can be blended.

  The drug of the present invention can be produced by a method known in the art. For example, when the drug of the present invention is a tablet, it can be produced in accordance with the section “General Tablet Preparation Guidelines”. Moreover, when it is a liquid agent, it can be manufactured according to the section of the Japanese Pharmacopoeia General Rules “Liquid Agent”.

  The agent of the present invention is effective for the prevention or treatment of seasonal A or B influenza, new influenza (influenza virus H1N1 2009) infection or highly pathogenic influenza. “Prevention” means preventing the onset of, or aggravation of, symptoms due to influenza virus infection, and the agent of the present invention is administered at the time when the risk of influenza infection is expected or at the early stage of infection. “Treatment” means that symptoms caused by influenza virus infection, particularly severe symptoms, are reduced or eliminated, and the agent of the present invention is administered when influenza virus infection is confirmed.

  Furthermore, the drug of the present invention effectively suppresses weight loss, appetite loss and ATP depletion associated with influenza infection, as shown in Test Examples described later. Therefore, the agent of the present invention is also an influenza infectious weight loss inhibitor, an influenza infectious appetite loss inhibitor, and an influenza infectious ATP depletion inhibitor.

  EXAMPLES Hereinafter, although an Example and a test example are shown and this invention is demonstrated in more detail, this invention is not limited to the following examples.

The reagents and experimental equipment used in the following examples are as follows.
(1) Ketamine: 500 mg for intramuscular injection [Daiichi Sankyo Propharma Co., Ltd.] Lot.GYA0015
(2) Seryl (Xylazine): 2% Injection [Bayer Yakuhin Co., Ltd.] Lot. KP05XAK
(3) PBS (Dulbecco phosphate buffered saline): [Nacalai Tesque Co., Ltd.] Lot. L7H4885
(4) Saline: Otsuka raw food injection [Otsuka Pharmaceutical Factory] Lot. M9F98
(5) DADA (Diisopropylamine dichloroacetate): [Daiichi Sankyo Co., Ltd.] Lot. XVA8056
(6) Thiamine hydrochloride (vitamin B1): [Wako Pure Chemical Industries, Ltd.] Lot. WK8618
(6) Sodium pyruvate: [Wako Pure Chemical Industries, Ltd.] Lot. CDJ4337
(7) Benfotiamine: [Daiichi Sankyo Co., Ltd.] Lot. XTA8056
(8) Calcium gluconate: [Nacalai Tesque Co., Ltd.] Lot. M9B3882
(9) Sodium gluconate: [Nacalai Tesque Co., Ltd.] Lot. M8T2159
(10) 0.5% CMC solution: 0.5 (w / v)% carboxymethylcellulose 400 solution: [Wako Pure Chemical Industries, Ltd.] Lot. STR3766
(11) Syringe: Terumo Syringe [Terumo Corporation] Lot. 081116F
(12) Injection needle: 30G 1/2 [Becton Dickinson Co., Ltd.] Lot. 305106
(13) Sonde needle: DISPOSABLE oral sonde [Fuchigami Co., Ltd.] Cat. 4202
Example 1 (Preparation of DADA Mixture 1)
To 100 mL of physiological saline,
・ DADA 0.5 g
・ Thiamine hydrochloride 0.075 g
・ Sodium pyruvate 1.0 g
・ Calcium gluconate 0.94 g
Were added and mixed to prepare DADA Mixture 1.
Example 2 (Preparation of DADA Mixture 2)
To 100 mL of physiological saline,
・ DADA 0.5 g
・ Benfotiamine 0.075 g
・ Sodium pyruvate 1.0 g
・ Calcium gluconate 0.94 g
Were added and mixed to prepare DADA Mixture 2.
Example 3 (Preparation of DADA Mixture 3)
To 100 mL of 0.5% CMC solution,
・ DADA 0.5 g
・ Thiamine hydrochloride 0.075 g
・ Sodium pyruvate 1.0 g
・ Calcium gluconate 0.94 g
Were added and mixed to prepare DADA Mixture 3.
Example 4 (Preparation of DADA Mixture 4)
To 100 mL of 0.5% CMC solution,
・ DADA 0.5 g
・ Thiamine hydrochloride 0.075 g
・ Sodium pyruvate 1.0 g
・ Sodium gluconate 2.1 g
Were added and mixed to prepare DADA Mixture 4.
Example 5 (Preparation of DADA Mixture 5)
To 100 mL of 0.5% CMC solution,
・ DADA 0.5 g
・ Benfotiamine 0.075 g
・ Sodium pyruvate 1.0 g
・ Calcium gluconate 0.47 g
Were added and mixed to prepare DADA Mixture 5.
Example 6 (Preparation of DADA Mixture 6)
To 100 mL of 0.5% CMC solution,
・ DADA 0.5 g
・ Benfotiamine 0.075 g
・ Calcium gluconate 0.47 g
Were added and mixed to prepare DADA Mixture 6.
Example 7 (Preparation of DADA Mixture 7)
To 100 mL of 0.5% CMC solution,
・ DADA 0.5 g
・ Calcium gluconate 0.47 g
Were added and mixed to prepare DADA Mixture 7.
Example 8 (Preparation of DADA Mixture 8)
To 100 mL of 0.5% CMC solution,
・ DADA 0.5 g
Was added to prepare DADA Mixture 8.
Test example 1
Viral infection tests were performed using 3-week-old female (C57B6 / 6J, Japan SLC, Inc) mice. The individual body weights of these mice were measured, and then divided into 4 groups (15 animals / 1 group) so that the average body weight was almost uniform. Three of them (45 animals in total) were designated as the infected group, and virus infection was carried out. Viral infection was provided by influenza virus (Influenza A / PR / 8/34: H1N1, from the Osaka University Microbial Disease Research Association) to mice that had undergone ketalal anesthesia (ketalal 62.6 mg / kg + seractal 12.4 mg / kg) ) 60 pfu (15 μL: 7.5 μL per nose). The remaining group (15 animals) was a non-infected group, and 15 μL of PBS was administered nasally instead of the virus.

  The administration of each drug to the mice of each infected group was carried out daily from the day after the virus infection (twice morning and evening, 0.1 mL each), physiological saline (control), DADA mixture 1 (Example 1), DADA mixture Agent 2 (Example 2) was administered intraperitoneally. Similarly, physiological saline was intraperitoneally administered to mice in the non-infected group. The survival rate and body weight of these mice were measured (every morning).

  The results are as shown in FIG. 1 (A: survival rate, B: body weight). In the control group (virus infection + saline administration group), 50% died 12 days after infection, and it was confirmed that the infectious dose of 60 pfu was a half-lethal dose.

In each group to which DADA mixture 1 (Example 1) and DADA mixture 2 (Example 2) were administered after virus infection, a better survival rate and an improvement effect on weight loss were observed compared to the control group. .
Test example 2
Viral infection tests were performed using 3-week-old female (C57B6 / 6J, Japan SLC, Inc) mice. The individual body weights of these mice were measured, and then divided into 4 groups (15 animals / 1 group) so that the average body weight was almost uniform. Three of them (45 animals in total) were designated as the infected group, and virus infection was carried out. For viral infection, mice treated with ketalal anesthesia (ketalal 62.6 mg / kg + seractal 12.4 mg / kg) were treated with 60 pfu of influenza virus (Influenza A / PR / 8/34: H1N1) (15 μL: unilateral 7.5 μL) Nasal infection). The remaining one group (15 animals) was a non-infected group, and 15 μL of PBS was administered nasally instead of the virus.

  The mice in each infected group were administered daily from the next day after virus infection (twice morning and evening, 0.1 mL), 0.5% CMC solution (control), DADA mixture 3 (Example 3), DADA mixture 4 ( Each of Example 4) was orally dosed. Similarly, the mice in the non-infected group were orally dosed with 0.5% CMC solution. The survival rate and body weight of these mice were measured (every morning).

The results are as shown in FIG. 2 (A: survival rate, B: body weight). DADA admixture 3 (Example 3) and DADA admixture 4 (Example 4) were observed to have a better survival rate and marked improvement in weight loss compared to the control group even when administered orally. It was done. The effect of improving body weight loss tended to be clearer in Test Example 2 administered orally than in Test Example 1 administered intraperitoneally.
Test example 3
Viral infection tests were performed using 3-week-old female (C57B6 / 6J, Japan SLC, Inc) mice. After measuring the individual body weights of these mice, the mice were divided into 4 groups (15 animals / group) so that the average body weight was almost uniform. Three of them (45 animals in total) were designated as the infection group, and virus infection was carried out. For virus infection, mice treated with ketalal anesthesia (ketalal 62.6 mg / kg + seractal 12.4 mg / kg) were treated with 60 pfu of influenza virus (Influenza A / PR / 8/34: H1N1) (15 μL: 7.5 μL for one nose) Nasal infection). The remaining group (15 animals) was a non-infected group, and 15 μL of PBS was administered nasally instead of the virus.

  Each drug administration to mice in each infected group was carried out daily from the next day after virus infection (twice morning and evening, 0.1 mL each), 0.5% CMC solution (control), DADA mixture 5 (Example 5), DADA mixture Agent 6 (Example 6) was orally dosed. Similarly, the mice in the non-infected group were orally dosed with 0.5% CMC solution. Changes in the survival rate, body weight, food intake, and water intake of these mice were measured (every morning).

The results are as shown in FIG. 3 (A: survival rate, B: body weight) and FIG. 4 (A: food intake, B: water intake). In the group to which DADA mixture 5 (Example 5) and DADA mixture 6 (Example 6) were respectively administered, a better survival rate and an improvement effect of weight loss were observed as compared with the control, and the amount of food intake and water intake There was also no significant difference in comparison with the control.
Test example 4
Viral infection tests were performed using 3-week-old female (C57B6 / 6J, Japan SLC, Inc) mice. The individual body weights of these mice were measured, and then divided into 5 groups (15 animals / 1 group) so that the average body weights were almost uniform. Of these, 4 groups (60 animals in total) were designated as infection groups, and virus infection was carried out. For virus infection, mice treated with ketalal anesthesia (ketalal 62.6 mg / kg + seractal 12.4 mg / kg) were treated with 60 pfu of influenza virus (Influenza A / PR / 8/34: H1N1) (15 μL: 7.5 μL for one nose) Nasal infection). The remaining group (15 animals) was a non-infected group, and 15 μL of PBS was administered nasally instead of the virus.

  The administration of each drug to the mice of each infection group was carried out daily from the day after the virus infection (twice morning and evening, 0.1 ml each), 0.5% CMC solution (control), DADA mixture 6 (Example 6), DADA Mixture 7 (Example 7) and DADA Mixture 8 (Example 8) were each orally dosed. Similarly, the mice in the non-infected group were orally dosed with 0.5% CMC solution. Changes in the survival rate, body weight, food intake, and water intake of these mice were measured (every morning).

  The results are as shown in FIG. 5 (A: survival rate, B: body weight) and FIG. 6 (A: food intake, B: water intake). The DADA mixed solution 8 containing only DADA (Example 8) gave better results in terms of survival rate than the control. The DADA mixture 6 containing DADA, gluconate and vitamin B1 (Example 6) and the DADA mixture 7 containing DADA and gluconate (Example 7) were also compared with the control. As a result, good results were obtained, and the body weight, food intake, and water intake were as good as those in the non-infected group.

From the above results, it was confirmed that DADA can be an active ingredient for influenza treatment and prevention drugs by itself. Furthermore, it was confirmed that the combined administration of DADA + gluconic acid or a salt thereof, or DADA + gluconic acid or a salt thereof + vitamin B1 has particularly excellent effects.
Test Example 5
Viral infection tests were performed using 3-week-old female (C57B6 / 6J, Japan SLC, Inc) mice. The individual body weights of these mice were measured, and then divided into 3 groups (15 animals / 1 group) so that the average body weight was almost uniform. Two of them (30 animals in total) were used as infection groups, and virus infection was carried out. Viral infection was caused by 50% survival up to Test Example 1-4 with influenza virus (Influenza A / PR / 8/34: H1N1) in mice treated with ketalal anesthesia (ketalal 62.6 mg / kg + seractal 12.4 mg / kg) The test was conducted under the condition that the rate of increase from 60 pfu to 200 pfu, which shows the rate, has a stronger effect on the metabolism of the virus. Nasal infection was performed by administering 15 μL: 7.5 μL of one nose. The remaining group (15 animals) was a non-infected group, and 15 μL of PBS was administered nasally instead of the virus.

  The administration of each drug to the mice of each infected group was carried out daily from the next day after virus infection (twice morning and evening, 0.1 ml each), 0.5% CMC solution (control) and DADA mixture 6 (Example 6), respectively. Orally dosed. Similarly, the mice in the non-infected group were orally dosed with 0.5% CMC solution. One week after infection, mice were measured for survival rate, change in body weight, food intake and water intake (every morning), and mice were killed by decapitation on the 7th day. The test (Test Example 6-8) was conducted.

The results up to the seventh day after virus infection are as shown in FIG. 7 (A: survival rate, B: body weight) and FIG. 8 (A: water intake, B: food intake). Even if the amount of virus to be infected was increased, the survival rate, body weight, water intake, and food intake until the seventh day of infection were not significantly different between the DADA mixture 6 (Example 6) administration group and the non-infection group. . In addition, when compared to the infection + 0.5% CMC solution (control), the DADA mixture 6 (Example 6) administration group significantly reduced body weight, water intake, and food intake.

Test Example 6
Viral infection tests were performed using 3-week-old female (C57B6 / 6J, Japan SLC, Inc) mice. The individual body weights of these mice were measured, and then divided into 3 groups (15 animals / 1 group) so that the average body weight was almost uniform. Two of them (30 animals in total) were used as infection groups, and virus infection was carried out. For viral infection, mice treated with ketalal anesthesia (ketalal 62.6 mg / kg + seractal 12.4 mg / kg) were treated with 200 pfu of influenza virus (Influenza A / PR / 8/34: H1N1) (15 μL: one nose 7.5 μL). Nasal infection). The remaining group (15 animals) was a non-infected group, and 15 μL of PBS was administered nasally instead of the virus.

The administration of each drug to the mice of each infected group was carried out daily from the next day after virus infection (twice morning and evening, 0.1 ml each), 0.5% CMC solution (control) and DADA mixture 6 (Example 6), respectively. Orally dosed. Similarly, the mice in the non-infected group were orally dosed with 0.5% CMC solution. Peripheral blood was collected from mice one week after infection, and blood glucose, lactic acid, ATP, and β-hydroxybutyric acid in the blood were measured by the following method.
1) Measurement of blood glucose level It was measured using Medisafe Mini GR-102 (TERUMO CORPOLATION JAPAN). According to the description in the instruction manual, a Medisafe Mini GR-102 was equipped with a Medisafe chip, and a small amount of blood was dropped on the chip for measurement.
2) Measurement of blood lactate level Measurement was performed using Lactate Pro LT-1710 (ARKRAY, Inc.). According to the description in the instruction manual, a lactate pro LT-1710 was equipped with a lactate prosensor, and blood was dropped on the sensor for measurement.
3) Measurement of blood β-blood β-hydroxybutyric acid As a representative example of blood ketone bodies, β-hydroxybutyric acid was measured. The β-hydroxybutyric acid value was measured using an apparatus of Precision Exceed (Abott Japan). According to the method of the instruction manual, β-ketone measuring electrode II was attached to Precision Exceed, and a small amount of blood was dropped on the sensor for measurement.
4) Measurement of blood ATP value Blood ATP value was measured using XL-ATP Kit according to the method described in the instruction manual (http://bio.aprosci.com/pdf/XL_ATP_kit.pdf). That is, after extracting ATP from blood, the amount of ATP contained in the blood was measured by luciferin-luciferase reaction.

The results are as shown in FIG. The blood glucose level was significantly reduced by influenza virus infection, but the DADA mixture 6 administration group showed the same value as that of the non-infected group mice, eliminating the effect of virus infection. The blood lactate level showed a significant increase due to influenza virus infection, but the increase was significantly reduced in the DADA mixture 6 administration group. Β-hydroxybutyric acid, a representative blood ketone body, showed a marked increase due to influenza virus infection. In the DADA 6 administration group, this increase was not only suppressed, but compared to the non-infected control group. Rather, a downward trend was observed.

Test Example 7
Viral infection tests were performed using 3-week-old female (C57B6 / 6J, Japan SLC, Inc) mice. The individual body weights of these mice were measured, and then divided into 3 groups (15 animals / 1 group) so that the average body weight was almost uniform. Two of them (30 animals in total) were used as infection groups, and virus infection was carried out. For viral infection, mice treated with ketalal anesthesia (ketalal 62.6 mg / kg + seractal 12.4 mg / kg) were treated with 200 pfu of influenza virus (Influenza A / PR / 8/34: H1N1) (15 μL: one nose 7.5 μL). Nasal infection). The remaining group (15 animals) was a non-infected group, and 15 μL of PBS was administered nasally instead of the virus.

  The administration of each drug to the mice of each infected group was carried out daily from the next day after virus infection (twice morning and evening, 0.1 ml each), 0.5% CMC solution (control) and DADA mixture 6 (Example 6), respectively. Orally dosed. Similarly, the mice in the non-infected group were orally dosed with 0.5% CMC solution. Brain, heart, muscle and liver were collected from these mice, and ATP of each tissue was measured 1 week after infection. ATP values in various organs were measured using XL-ATP Kit as described in the instruction manual.

The results are shown in FIG. 10 as the amount of ATP per amount of protein in the extract. In the brain, there was no difference in ATP level between the infected group, the non-infected group, and the group administered with DADA mixture 6. On the other hand, in the heart, liver, and muscle, ATP levels decreased significantly compared to the non-infected group due to influenza virus infection, and the decrease in ATP level was improved in the DADA mixture 6 administration group. Recovered to the same level.

Test Example 8
Viral infection tests were performed using 3-week-old female (C57B6 / 6J, Japan SLC, Inc) mice. The individual body weights of these mice were measured, and then divided into 3 groups (15 animals / 1 group) so that the average body weight was almost uniform. Two of them (30 animals in total) were used as infection groups, and virus infection was carried out. For viral infection, mice treated with ketalal anesthesia (ketalal 62.6 mg / kg + seractal 12.4 mg / kg) were treated with 200 pfu of influenza virus (Influenza A / PR / 8/34: H1N1) (15 μL: one nose 7.5 μL). Nasal infection). The remaining group (15 animals) was a non-infected group, and 15 μL of PBS was administered nasally instead of the virus.

  The administration of each drug to the mice of each infected group was carried out daily from the next day after virus infection (twice morning and evening, 0.1 ml each), 0.5% CMC solution (control) and DADA mixture 6 (Example 6), respectively. Orally dosed. Similarly, the mice in the non-infected group were orally dosed with 0.5% CMC solution. Brain, heart, muscle and liver were collected from these mice, and pyruvate dehydrogenase (PDH) in each tissue one week after infection was handled by Pyruvate Dehydrogenase Enzyme Activity Microplate Assay Kit MSP18 (MitoSciences). Samples were extracted from various tissues according to the description (http://www.mitosciences.com/PDF/pyruvate_dehydrogenase_enzyme_activity_microplate_assay_kit_protocol.pdf) and measured using a measurement kit.

  The result is as shown in FIG. PDH activity in each tissue showed a trend similar to ATP level. That is, PDH activity decreased in the heart, liver, and muscle other than the brain due to influenza virus infection, and the DADA mixture 6 administration group showed a tendency to recover to a non-infection level. This result suggests that glucose metabolism involving PDH is involved in the improvement of ATP level in each tissue after infection shown in Test Example 7.

  ADVANTAGE OF THE INVENTION By this invention, the drug which is effective in preventing the onset of influenza, especially the seriousness, or the improvement of a symptom is provided by using DADA as an active ingredient. The agent of the present invention can also be provided as an inhibitor of weight loss associated with influenza infection, an inhibitor of appetite loss, and an ATP depletion inhibitor.

Claims (5)

A therapeutic or prophylactic agent for influenza virus infection containing diisopropylamine dichloroacetate. Furthermore, the therapeutic agent or preventive agent of Claim 1 containing gluconic acid or its salt. Furthermore, the therapeutic agent or preventive agent of Claim 2 containing vitamin B1 class. The therapeutic or preventive agent according to any one of claims 1 to 3, wherein the influenza virus is a seasonal influenza virus type A or B, a new influenza virus (influenza virus H1N1 2009), or a highly pathogenic influenza virus. . A method for treating or preventing influenza virus infection, comprising administering an effective amount of the agent according to any one of claims 1 to 4 to a mammal.